28 December 2024
We are NovaMedica — a Russian pharmaceutical company that develops, manufactures, and promotes innovative medications addressing the unique needs of patients with CNS disorders.
We value and take pride in the achievements of 2024!
I extend my gratitude to every employee of the NovaMedica group of companies for their hard work, intelligence, and time dedicated to the development of the company, care for patients, and contributions to expanding medical knowledge on the diagnosis and treatment of chronic CNS disorders.
Trust and teamwork enable us to improve and multiply our successes! The invaluable experience of working together — small victories, challenges, new insights, and the search for unconventional solutions — has become the most precious capital that we reinvest in the future. For the sake of six and two new patients diagnosed with CDKL5, we accomplished the impossible — ensuring a record-breaking supply of an unregistered medication in Russia.
The values of our company have been tested repeatedly, and we are convinced that WE succeed together when we prioritize the interests of patients, implement innovative solutions, and take full responsibility for everything we do!
With enthusiasm and optimism, we plan for a new 2025!
Wishing you happiness and good health!
General Director of NovaMedica
Elena LITVINOVA
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025